1. Home
  2. APPF vs TGTX Comparison

APPF vs TGTX Comparison

Compare APPF & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

APPF

AppFolio Inc.

N/A

Current Price

$204.24

Market Cap

7.8B

Sector

Technology

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$53.62

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
APPF
TGTX
Founded
2006
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
8.5B
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
APPF
TGTX
Price
$204.24
$53.62
Analyst Decision
Strong Buy
Buy
Analyst Count
9
8
Target Price
★ $236.04
$69.71
AVG Volume (30 Days)
217.5K
★ 1.4M
Earning Date
10-29-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1746.67
EPS
★ 2.36
0.17
Revenue
★ $950,822,000.00
$2,785,000.00
Revenue This Year
$18.19
$55.80
Revenue Next Year
$17.45
$37.28
P/E Ratio
★ $83.63
$328.53
Revenue Growth
★ 19.72
N/A
52 Week Low
$142.56
$26.76
52 Week High
$264.87
$59.30

Technical Indicators

Market Signals
Indicator
APPF
TGTX
Relative Strength Index (RSI) 46.67 52.86
Support Level $200.57 $51.76
Resistance Level $227.62 $58.26
Average True Range (ATR) 7.13 2.13
MACD -2.23 -0.16
Stochastic Oscillator 35.55 56.39

Price Performance

Historical Comparison
APPF
TGTX

About APPF AppFolio Inc.

AppFolio Inc provides cloud-based software solutions for the real estate industry. Its property management software offers property managers an end-to-end solution to their business needs. The group's products include cloud-based property management software (Appfolio Property Manager). Its solutions are AppFolio Property Manager Core, AppFolio Property Manager Plus, and AppFolio Property Manager Max. It also offers value-added services, such as screening, risk mitigation, and electronic payment services. Its markets are Single-Family, Multifamily, Student Housing, Affordable Housing, Community Associations, Commercial, and Investment Management. The business activity of the firm predominantly functions in the United States and it generates revenue in the form of subscription fees.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: